DK171826B1 - Ca2+-afhængigt monoklonalt antistof mod protein C, hybridomacellelinie til produktion af antistoffet, fremgangsmåde til isolation af protein C, fremgangsmåde til fremstilling af antistoffet og polypeptid til brug ved fremgangsmåden - Google Patents

Ca2+-afhængigt monoklonalt antistof mod protein C, hybridomacellelinie til produktion af antistoffet, fremgangsmåde til isolation af protein C, fremgangsmåde til fremstilling af antistoffet og polypeptid til brug ved fremgangsmåden Download PDF

Info

Publication number
DK171826B1
DK171826B1 DK209090A DK209090A DK171826B1 DK 171826 B1 DK171826 B1 DK 171826B1 DK 209090 A DK209090 A DK 209090A DK 209090 A DK209090 A DK 209090A DK 171826 B1 DK171826 B1 DK 171826B1
Authority
DK
Denmark
Prior art keywords
protein
antibody
hpc
peptide
binding
Prior art date
Application number
DK209090A
Other languages
Danish (da)
English (en)
Other versions
DK209090A (da
DK209090D0 (da
Inventor
Charles T Esmon
Naomi L Esmon
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of DK209090A publication Critical patent/DK209090A/da
Publication of DK209090D0 publication Critical patent/DK209090D0/da
Application granted granted Critical
Publication of DK171826B1 publication Critical patent/DK171826B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK209090A 1988-12-30 1990-08-30 Ca2+-afhængigt monoklonalt antistof mod protein C, hybridomacellelinie til produktion af antistoffet, fremgangsmåde til isolation af protein C, fremgangsmåde til fremstilling af antistoffet og polypeptid til brug ved fremgangsmåden DK171826B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29244788A 1988-12-30 1988-12-30
US29244788 1988-12-30
PCT/US1989/005851 WO1990007524A1 (en) 1988-12-30 1989-12-28 Monoclonal antibody against protein c
US8905851 1989-12-28

Publications (3)

Publication Number Publication Date
DK209090A DK209090A (da) 1990-08-30
DK209090D0 DK209090D0 (da) 1990-08-30
DK171826B1 true DK171826B1 (da) 1997-06-23

Family

ID=23124711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK209090A DK171826B1 (da) 1988-12-30 1990-08-30 Ca2+-afhængigt monoklonalt antistof mod protein C, hybridomacellelinie til produktion af antistoffet, fremgangsmåde til isolation af protein C, fremgangsmåde til fremstilling af antistoffet og polypeptid til brug ved fremgangsmåden

Country Status (11)

Country Link
EP (1) EP0407544B1 (fi)
JP (1) JP2559537B2 (fi)
KR (1) KR940002033B1 (fi)
AT (1) ATE122057T1 (fi)
AU (2) AU641634B2 (fi)
CA (1) CA2006684C (fi)
DE (1) DE68922491T2 (fi)
DK (1) DK171826B1 (fi)
ES (1) ES2074562T3 (fi)
FI (1) FI101476B1 (fi)
WO (1) WO1990007524A1 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DK0658168T3 (da) * 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5532136A (en) * 1993-06-22 1996-07-02 Bionebraska, Inc. Monoclonal antibody assay and kit for detecting metal cations in body fluids
JPH08512323A (ja) * 1993-07-09 1996-12-24 スミスクライン・ビーチャム・コーポレイション タンパク精製方法
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
AU710106B2 (en) * 1994-06-10 1999-09-16 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2647706B1 (en) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI673063B (zh) * 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用

Also Published As

Publication number Publication date
AU669540B2 (en) 1996-06-13
DK209090A (da) 1990-08-30
FI904262A0 (fi) 1990-08-29
DE68922491T2 (de) 1995-11-09
WO1990007524A1 (en) 1990-07-12
FI101476B (fi) 1998-06-30
AU4968390A (en) 1990-08-01
AU641634B2 (en) 1993-09-30
ATE122057T1 (de) 1995-05-15
EP0407544A1 (en) 1991-01-16
CA2006684A1 (en) 1990-06-30
CA2006684C (en) 1996-12-17
ES2074562T3 (es) 1995-09-16
KR910700266A (ko) 1991-03-14
JP2559537B2 (ja) 1996-12-04
KR940002033B1 (ko) 1994-03-14
EP0407544B1 (en) 1995-05-03
JPH03504332A (ja) 1991-09-26
FI101476B1 (fi) 1998-06-30
DE68922491D1 (de) 1995-06-08
AU4422893A (en) 1994-01-27
DK209090D0 (da) 1990-08-30

Similar Documents

Publication Publication Date Title
US5336610A (en) Method for purification of the zymogen of protein C or the heavy chain thereof using monoclonal antibody HPC-4
DK171826B1 (da) Ca2+-afhængigt monoklonalt antistof mod protein C, hybridomacellelinie til produktion af antistoffet, fremgangsmåde til isolation af protein C, fremgangsmåde til fremstilling af antistoffet og polypeptid til brug ved fremgangsmåden
US7501117B2 (en) Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US5260274A (en) Factor VIII binding domain of von Willebrand Factor
US5679639A (en) Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
USRE38202E1 (en) Antibodies specific for a haemostatic protein, their use for isolating protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5279956A (en) Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5190919A (en) Antihemostatic factor vii peptides
EP0972781B1 (en) Proteins polypeptides and uses thereof
CA1258242A (en) Urokinase zymogen and composition containing the same
EP0592600B1 (en) Proteins s polypeptides and uses thereof
CA2105863A1 (en) Compositions and methods to inhibit the activation of active factor xiii
JPS6062981A (ja) 線維素溶解酵素
JPH04218368A (ja) プラスミノーゲン・アクチベーター前駆体の製造法

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired